conducted a phase Ib proof-of-concept trial in which patients with advanced WDLPS and DDLPS received concomitant siremadlin, a selective MDM2 inhibitor, with ribociclib, a selective CDK4/6 inhibitor. This evidence concerns the gene MDM2 and dedifferentiated liposarcoma.